• Subscribe
  • About us
  • Advertise with us

NeuroSens

Menu

Skip to content
  • Home
  • Neurology
  • Psychiatry

Topic: BIOMARKERS IN MS

REPORT FROM EAN 2024 – TUESDAY, JULY 2, 2024

July 2, 2024  

Use of neurofilament-light chain (NfL) in the management of patients with multiple sclerosis

June 27, 2024  

New guidance on use of sNfL in practice

May 27, 2024  

REPORT FROM AAN 2024 – MONDAY, APRIL 15

April 15, 2024  

Fluid biomarkers: theory and practice

March 18, 2024  

New consensus statement on MRI biomarkers in MS

February 20, 2024  

McDonald criteria 2024: what changes can we expect?

January 30, 2024  

NfL a marker of microglial activation

December 6, 2023  

Biomarkers after stopping treatment may identify at-risk MS patients

November 30, 2023  

Neurofilament-light chain (NfL) as a biomarker of response to higher-efficacy disease-modifying therapies

November 22, 2023  
Previous
1
2
3
4
5
Next

Browse by Topic

  • MS (442)
  • EAN 2026 (2)
  • CLINICAL CASES (21)
  • AAN 2026 (3)
  • ACTRIMS Forum 2026 (4)
  • EPILEPSY (38)
  • AES 2025 (1)
  • BIOMARKERS IN MS (61)
  • ECTRIMS 2025 (7)
  • Library (18)
  • EAN 2025 (2)
  • AAN 2025 (5)
  • ACTRIMS 2025 (6)
  • AES 2024 (1)
  • ECTRIMS 2024 (6)
  • EAN 2024 (3)
  • AD (85)
  • AAN 2024 (5)
  • ACTRIMS Forum 2024 (2)
  • PD (77)
  • COVID-19 (58)
  • MIGRAINE (25)
  • DEPRESSION (36)
  • STROKE (22)
  • SCHIZOPHRENIA (25)
  • DEMENTIA (10)
  • SLEEP (2)
  • PAIN (3)
  • BPD (4)
  • ALS (1)

Popular Posts

  • Proton pump inhibitors linked to neurological conditions posted on November 29, 2019
  • Ultomiris (ravulizumab) now publicly reimbursed in gMG posted on April 7, 2026
  • Ofatumumab – new data on efficacy and safety posted on April 14, 2025
Copyright 2026 Lind Publishing Inc All rights reserved. Developed by Integration New Media, INC. (INM)
Contact Us Terms and Conditions